Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human V <sub>H</sub> 1-2-rearranging mouse models

H Himanshu Batra S Sai Luo (Howard Hughes Medical Institute, Boston Children’s Hospital) K Kevin O. Saunders J Jaclyn S. Higgins (Departments of Epidemiology and Microbiology and Immunology, University of North Carolina at Chapel Hill) F Fanchong Jian (Biomedical Pioneering Innovation Center, Peking University) J Jun Zhang M Md Golam Kibria (Division of Molecular Medicine, Boston Children’s Hospital, Harvard Medical School) G G. M. Jonaid (Division of Molecular Medicine, Boston Children’s Hospital, Harvard Medical School) Q Qingchen J. Zhou (Howard Hughes Medical Institute, Boston Children’s Hospital) A Amanda Eaton (Duke Human Vaccine Institute, Duke University School of Medicine) K Kenneth Cronin (Duke Human Vaccine Institute, Duke University School of Medicine) M Michael L. Mallory (Departments of Epidemiology and Microbiology and Immunology, University of North Carolina at Chapel Hill) M Melissa Mattocks R Robert J. Edwards R Robert Parks (Duke Human Vaccine Institute, Duke University School of Medicine) E Esther M. Lee (Duke Human Vaccine Institute, Duke University School of Medicine) A Adam Yongxin Ye A Aimee Chapdelaine Williams (Howard Hughes Medical Institute, Boston Children’s Hospital) G Geeyoun Jung (Howard Hughes Medical Institute, Boston Children’s Hospital) K Katayoun Mansouri (Duke Human Vaccine Institute, Duke University School of Medicine) S S. Munir Alam (Duke Human Vaccine Institute, Duke University School of Medicine) D David C. Montefiori (Duke Human Vaccine Institute, Duke University Medical Center) M Ming Tian (State Key Laboratory of Organic–Inorganic Composites, College of Materials Science and Engineering) R Ralph S. Baric Y Yunlong Cao (Biomedical Pioneering Innovation Center, Peking University) B Barton F. Haynes B Bing Chen F Frederick W. Alt

Abstract

During V(D)J recombination, antibody diversity is enhanced by nontemplated junctional modifications that generate immensely diverse heavy chain (HC) and light chain (LC) complementarity-determining 3 antigen-contact regions (CDR3s). We previously developed a mouse model that generates diverse antibody repertoires by rearranging a single human V H 1-2 and Vκ1-33, associated with highly diverse CDR3s generated by V(D)J recombination with mouse Ds and/or Js. Immunization of this model with SARS-CoV-2 D614G spike elicited an antibody that potently neutralized SARS-CoV-2 variants through Omicron BA.2.754. Here, we report a related mouse model in which a single V H 1-2 rearranges to human D3-3 and J H 6, generating diverse HC-CDR3s much longer on average than those of our prior model. Omicron BA.4/.5 spike-ferritin nanoparticle-immunization of the new model elicited four highly related humanized antibodies that potently neutralize downstream Omicron subvariants. All four antibodies had 12 AA HC-CDR3s with two aromatic amino acids that engage an epitope comprising a hydrophobic patch opened-up by early Omicron lineage mutations and conserved in subsequent variants. Immunization of our prior, shorter CDR3-based model, elicited slightly less potent neutralizing antibodies that bound the same Omicron epitope, and were similar in all other aspects to those from the long, fully human CDR3 model. One tested antibody from each set reduced lung viral titers in a mouse-adapted BQ1.1 challenge. The antibodies we describe are related in their epitope recognition to recently described antibodies from Omicron-infected humans. These studies validate the utility of single human V H - and Vκ-rearranging mice for discovering humanized antibodies that neutralize emerging pathogens.

Article Details

Volume / Issue Vol. 123, Issue 13
Published March 31, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (28)

H

Himanshu Batra

S

Sai Luo

Howard Hughes Medical Institute, Boston Children’s Hospital

K

Kevin O. Saunders

J

Jaclyn S. Higgins

Departments of Epidemiology and Microbiology and Immunology, University of North Carolina at Chapel Hill

F

Fanchong Jian

Biomedical Pioneering Innovation Center, Peking University

J

Jun Zhang

M

Md Golam Kibria

Division of Molecular Medicine, Boston Children’s Hospital, Harvard Medical School

G

G. M. Jonaid

Division of Molecular Medicine, Boston Children’s Hospital, Harvard Medical School

Q

Qingchen J. Zhou

Howard Hughes Medical Institute, Boston Children’s Hospital

A

Amanda Eaton

Duke Human Vaccine Institute, Duke University School of Medicine

K

Kenneth Cronin

Duke Human Vaccine Institute, Duke University School of Medicine

M

Michael L. Mallory

Departments of Epidemiology and Microbiology and Immunology, University of North Carolina at Chapel Hill

M

Melissa Mattocks

R

Robert J. Edwards

R

Robert Parks

Duke Human Vaccine Institute, Duke University School of Medicine

E

Esther M. Lee

Duke Human Vaccine Institute, Duke University School of Medicine

A

Adam Yongxin Ye

A

Aimee Chapdelaine Williams

Howard Hughes Medical Institute, Boston Children’s Hospital

G

Geeyoun Jung

Howard Hughes Medical Institute, Boston Children’s Hospital

K

Katayoun Mansouri

Duke Human Vaccine Institute, Duke University School of Medicine

S

S. Munir Alam

Duke Human Vaccine Institute, Duke University School of Medicine

D

David C. Montefiori

Duke Human Vaccine Institute, Duke University Medical Center

M

Ming Tian

State Key Laboratory of Organic–Inorganic Composites, College of Materials Science and Engineering

R

Ralph S. Baric

Y

Yunlong Cao

Biomedical Pioneering Innovation Center, Peking University

B

Barton F. Haynes

B

Bing Chen

F

Frederick W. Alt